Legflow药物涂层球囊联合Supera支架与单纯Supera支架治疗股浅动脉中长病变的RAPID随机试验短期结果
RAPID多中心随机试验将160例股浅动脉中长病变患者按1:1分配至Legflow紫杉醇药物涂层球囊(PEB)联合Supera支架组或单纯Supera支架组,比较1年通畅率。意向治疗分析显示两组1年主要通畅率分别为68.3%与62.0%(p=0.900),差异无统计学意义;符合方案分析中PEB组主要通畅率数值更高但未达显著性(p=0.273)。结论认为Legflow PEB联合Supera支架安全可行,但未显著优于单纯支架。
要点
- Legflow PEB联合Supera支架1年主要通畅率68.3%,单纯支架62.0%,差异无统计学意义。
- 符合方案分析中PEB组1年主要通畅率74.7% vs 62.0%,p=0.273,未达显著性。
- 两组临床驱动的靶病变血运重建豁免率分别为83.0%和77.8%,p=0.277。
核心结论
- Legflow PEB联合Supera支架治疗股浅动脉中长病变安全可行,但短期通畅率未显著优于单纯Supera支架。
研究设计与样本
- 多中心随机对照试验(RAPID,ISRCTN47846578),1:1随机纳入160例Rutherford 2-6级缺血患者,平均年龄67岁,男性102例。
- 病变为股浅动脉中长病变,PEB+支架组与单纯支架组平均病变长度分别为15.8±7.4 cm和15.8±7.6 cm。
主要发现
- 意向治疗分析1年主要通畅率:PEB+支架组68.3%(95% CI 56.7%-79.9%),单纯支架组62.0%(95% CI 49.1%-74.9%),p=0.900。
- 符合方案分析1年主要通畅率:PEB+支架组74.7%(95% CI 63.1%-86.3%),单纯支架组62.0%(95% CI 49.1%-74.9%),p=0.273。
- 符合方案分析12个月二次通畅率:PEB+支架组89.0%(95% CI 80.6%-97.4%),单纯支架组98.0%(95% CI 94.1%-100%),p=0.484。
- 符合方案分析12个月免于临床驱动靶病变血运重建率:PEB+支架组83.0%(95% CI 72.8%-93.2%),单纯支架组77.8%(95% CI 66.6%-89.0%),p=0.277。
临床怎么用
- 对于股浅动脉中长病变,Legflow PEB联合Supera支架可作为安全可行的治疗选择,但短期疗效未显著优于单纯支架。
- 试验中至少70%患者存在闭塞病变,提示该联合方案在复杂病变中具有可行性。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report a randomized trial comparing the Legflow paclitaxel-eluting balloon (PEB) + Supera stenting to Supera stenting alone in patients with intermediate to long superficial femoral artery (SFA) lesions. METHODS: The multicenter RAPID trial ( controlled-trials.com ; identifier ISRCTN47846578) randomized (1:1) 160 patients (mean age 67 years; 102 men) with Rutherford category 2-6 ischemia to treatment with Legflow PEB + Supera stent or Supera stent alone in intermediate to long SFA lesions (mean lesion length 15.8±7.4 vs 15.8±7.6 cm, respectively). The efficacy outcome was primary patency, defined as freedom from restenosis on duplex ultrasound or angiography. RESULTS: Baseline characteristics including the percentage of occlusions were similar between groups. In the intention-to-treat analysis, the estimated primary patency at 1 year was 68.3% (95% CI 56.7% to 79.9%) in the PEB + Supera group vs 62.0% (95% CI 49.1% to 74.9%) in the Supera group (p=0.900). Per-protocol analysis showed a 12-month primary patency estimate of 74.7% (95% CI 63.1% to 86.3%) in the PEB + Supera group vs 62.0% (95% CI 49.1% to 74.9%) in the control group (p=0.273). Secondary patency estimates at 12 months (per-protocol analysis) were 89.0% (95% CI 80.6% to 97.4%) vs 98.0% (95% CI 94.1% to 100%; p=0.484); the estimates for freedom from clinically driven target lesion revascularization (CD-TLR) were 83.0% (95% CI 72.8% to 93.2%) and 77.8% (95% CI 66.6% to 89.0%; p=0.277), respectively. CONCLUSION: The short-term results from the multicenter RAPID randomized controlled trial indicate that the Legflow PEB is safe and feasible for the treatment of intermediate to long SFA lesions. In this trial, at least 70% of the patients suffered an occlusion. The PEB group had higher rates of primary patency and freedom from CD-TLR, although there were no statistically significant differences vs controls.
引用
- de Boer SW, van den Heuvel DAF, de Vries-Werson DAB, et al. Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions. J Endovasc Ther. 2017. PMID: 28795638. doi:10.1177/1526602817725062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。